VolitionRx reports FY2024 revenue up 59% to $1.2M; cash at $3.3M

VOLITIONRX LTD

2025-Q1 EPS reported -$0.06 revenue$246,385

Revenue $1.2M in 2024, up 59% YoY; Nu.Q Vet revenue up 75%, Nu.Q Discover up 40%.
Operating expenses down 23% YoY; post-year-end raised $2.3M equity and $1.8M non-dilutive funding.
Sold ~120,000 Nu.Q Vet Cancer Tests; available in 20+ countries; active commercial discussions for human diagnostics.
Goal to be cash neutral in 2025 via licensing receipts and revenue.
Board strengthened with new Chair Timothy Still and Director Dr. Ethel Rubin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.